NASA officials say the agency is on track to decide by the end of the year how to revise the Mars Sample Return (MSR) architecture to lower its costs and shorten its schedule.
In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional ...